2641216-67-1

Name	MK-1084
CAS	2641216-67-1

Synonyms

MK-1084

show less show more

Chemical Properties

form	Solid
color	White to off-white

Hazard Information

Uses

MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 exhibits anticancer activity and can be used either alone or in combination with pembrolizumab (HY-P9902) for cancer research[1].

in vivo

MK-1084 (10-30 mg/kg, po for 14 days) exhibits antitumor efficacy in mouse MiaPaCa-2 xenograft models^[2].
MK-1084 exhibits a good pharmacokinetic characteristics with a plasma clearance of 22 mL/min/kg, a mean residence time MRT of 1.1 h and an oral bioavailability of 61%^[2].

Animal Model:	Mouse MiaPaCa-2 xenograft models^[2]
Dosage:	10-30 mg/kg
Administration:	po for 14 days
Result:	Inhibited tumor growth.

References

[1] Rojas C, et al. 663P Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC[J]. Annals of Oncology, 2023, 34: S466-S467.
[2] Ma X, et al., Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor. J Med Chem. 2024 Jul 11;67(13):11024-11052. DOI:10.1021/acs.jmedchem.4c00572

Supplier

Nantong QuanYi Biotechnology Co., Ltd

Telephone0513-66337626 18051384581

Websitehttps://www.chemhifuture.com/

Suzhou Haiben Pharmaceutical Co., Ltd

Telephone14760821013 13564957716

Website

Suzhou Meidi Senuo Pharmaceutical Technology Co., Ltd.

Telephone 13771642864

Websitehttps://www.chemicalbook.com/ShowSupplierProductsList1659441/0.htm

Afflon Pharmaceutical (Sichuan) Co., Ltd.

Telephone 18382338475

Website

PROMPT×

PROMPT
The What'sApp is temporarily not supported in mainland China

Cancel

Determine

Send Inquriy